ClinicalTrials.gg
Not yet recruitingNCT07942805Updated Nov 17, 2026

Dexamethasone Doses and Glycemic Response in Diabetic Cholecystectomy

A Phase 4 interventional study of Dexamethasone 4mg and Dexamethasone 8 mg in Diabetes Mellitus and Hyperglycemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Assiut University · Phase 4, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Diabetes Mellitus by Assiut University — 21 open to participants now, 21 under way, none of them phase 3. Diabetes Mellitus · Assiut University.

Started
2026
with 6 others
Phase 4
2 of 33
1 open now
Primary completion
2027-11
later than 18 of 20 live
Registered
33rd of 33
by date

Among the 33 studies in Diabetes Mellitus by Assiut University, this one is one of 7 that started in 2026, is one of 2 in phase 4, reaches primary completion later than 18 of the 20 other live ones, and was the 33rd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

21 of the 33 studies in Diabetes Mellitus by Assiut University are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Diabetes Mellitus by Assiut University, or all of them as a file.
02

Study summary

This randomized double-blind controlled trial aims to compare the effects of two different doses of intraoperative intravenous dexamethasone (4 mg versus 8 mg) versus placebo on perioperative glycemic response in adult patients with diabetes mellitus undergoing laparoscopic cholecystectomy.

Read the detailed description

Diabetes mellitus is a common comorbidity in patients undergoing surgery. Perioperative hyperglycemia is associated with increased morbidity. Dexamethasone is frequently administered intraoperatively for its antiemetic and anti-inflammatory effects, but it can cause hyperglycemia.

This randomized double-blind trial will allocate adult patients with established diabetes mellitus scheduled for elective laparoscopic cholecystectomy into three groups: Group I (4 mg dexamethasone), Group II (8 mg dexamethasone), and Group III (placebo). Blood glucose will be measured at predefined time points using a glucometer. The primary outcome is the maximum recorded perioperative blood glucose concentration within 24 hours after dexamethasone administration.

03

Conditions studied

  • Diabetes Mellitus
  • Hyperglycemia

Keywords

  • Dexamethasone
  • Diabetes mellitus
  • Laparoscopic cholecystectomy
  • Glycemic response
  • Perioperative hyperglycemia
  • Assiut
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Adult patients aged 18 to 60 years.
  • Established diabetes mellitus.
  • Scheduled for elective laparoscopic cholecystectomy under general anesthesia.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • - Patient refusal.
  • Morbid obesity, cardiac diseases, hepatic diseases, or renal diseases.
  • Endocrine disorders affecting glucose metabolism other than diabetes mellitus.
  • Type 1 diabetes mellitus requiring continuous insulin infusion.
  • Poorly controlled diabetes mellitus ( > 9.0%).
  • III-IV.
  • Recent parenteral or oral therapy.
  • Allergy to dexamethasone.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    4 mg Dexamethasone

    Patients will receive 4 mg of intravenous dexamethasone diluted in 0.9% normal saline to 5 mL, administered intravenously over 30 seconds.

    Drug: Dexamethasone 4mg

  • Experimental
    8 mg Dexamethasone

    Patients will receive 8 mg of intravenous dexamethasone diluted in 0.9% normal saline to 5 mL, administered intravenously over 30 seconds.

    Drug: Dexamethasone 8 mg

  • Placebo comparator
    Placebo

    Patients will receive an equivalent volume of 0.9% normal saline intravenously as placebo.

    Drug: Placebo (0.9% Normal Saline)

Interventions

  • DrugDexamethasone 4mg

    Intravenous 4 mg dexamethasone diluted in 0.9% normal saline to 5 mL, administered over 30 seconds.

    Also known as: Dexamethasone

  • DrugDexamethasone 8 mg

    Intravenous 8 mg dexamethasone diluted in 0.9% normal saline to 5 mL, administered over 30 seconds.

    Also known as: Dexamethasone

  • DrugPlacebo (0.9% Normal Saline)

    Equivalent volume of 0.9% normal saline intravenously.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Maximum Perioperative Blood Glucose Concentration

    Maximum recorded perioperative blood glucose concentration in mg/dL within 24 hours after dexamethasone administration, measured by finger-prick capillary blood glucose using a glucometer.

    Time frame: At 24 hours

Secondary outcomes

  1. Time to Peak Blood Glucose Concentration

    Mean time in hours from dexamethasone administration to peak blood glucose concentration.

    Time frame: At 24 hours

  2. Proportion of Patients Developing Hyperglycemia

    Proportion of patients developing blood glucose \> 180 mg/dL.

    Time frame: At 24 hours

  3. Proportion of Patients Developing Severe Hyperglycemia

    Proportion of patients developing blood glucose \> 200 mg/dL or \> 250 mg/dL.

    Time frame: At 24 hours

  4. Requirement for Rescue Insulin

    Proportion of patients requiring rescue insulin during the first 24 postoperative hours.

    Time frame: At 24 hours

  5. Incidence of Hypoglycemia

    Proportion of patients developing blood glucose \< 70 mg/dL.

    Time frame: At 24 hours

  6. Postoperative Nausea and Vomiting

    Incidence of postoperative nausea and vomiting.

    Time frame: At 24 hours

  7. Surgical Site Infection

    Incidence of surgical site infection.

    Time frame: At 30 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 149 non-industry phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 12 months is below that.

Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 26, 2026
Primary completionEst.
Nov 26, 2027
CompletionEst.
Feb 25, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942805
Lead sponsor
Assiut University
Responsible party
Arwa Mamdouh Mostafa Darwish (Resident Physician, Department of Anesthesia, Intensive Care and Pain Management, Assiut University) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 26, 2026 (estimated)
Primary completion
Nov 26, 2027 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Arwa M Mostafa, Resident
Contact
Arwa.18313470@med.aun.edu.eg
01012885077
Ola M Wahba, prof
study chair · Anaesthesia , ICU and pain management Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion